References
- CollinsRMacMahonSBlood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart diseaseBr Med Bull1994502722988205459
- ManciaGLaurentSAgabiti-RoseiEReappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force documentJ Hypertens2009272121215819838131
- GradmanAHRationale for triple-combination therapy for management of high blood pressureJ Clin Hypertens (Greenwich)20101286987821054774
- WrightJTJrDunnJKCutlerJAOutcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinoprilJAMA20052931595160815811979
- SalahuddinAMushtaqMMatersonBJCombination therapy for hypertension 2013: an updateJ Am Soc Hypertens2013740140723751186
- KizilirmakPBerktasMUresinYYildizOBThe efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic: a systematic review and meta-analysisJ Clin Hypertens (Greenwich)20131519320023458592
- NeutelJMSmithDHHypertension management: rationale for triple therapy based on mechanisms of actionCardiovasc Ther20133125125823121769
- ManciaGFagardRNarkiewiczK2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)Eur Heart J2013342159221923771844
- KjeldsenSEAksnesTARuilopeLMClinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoringDrugs R D201414314324842751
- de la SierraABarriosVBlood pressure control with angiotensin receptor blocker-based three-drug combinations: key trialsAdv Ther20122940141522610686
- PanjabiSLaceyMBancroftTCaoFTreatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patientsJ Am Soc Hypertens20137466023321404
- BramlagePHasfordJBlood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment–a reviewCardiovas Diabetol2009818
- Drugs@FDA [homepage on the Internet]Silver SpringU.S. Food and Drug Administration2014 Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/Accessed November 21, 2014
- OparilSMelinoMLeeJFernandezVHeyrmanRTriple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group studyClin Ther2010321252126920678674
- KereiakesDJChrysantSGIzzoJLJrOlmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY studyCardiovasc Diabetol20121113423110471
- PunziHAEfficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn studyTher Adv Cardiovasc Dis20148122124492985
- VolpeMde la SierraAAmmentorpBLaeisPOpen-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertensionAdv Ther20143156157424760656
- WeirMRShojaeeAMaaJFEfficacy of amlodipine/olmesartan medoxomil ± hydrochlorothiazide in patients aged ≥65 or <65 years with uncontrolled hypertension on prior monotherapyPostgrad Med201312512413423816778
- OgiharaTRakugiHIkegamiHMikamiHMasuoKEnhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensivesAm J Hypertens199583163207794582
- WangOJKrumholzHMClinical trial participation: are we studying the patients we are trying to treat?Eur J Heart Failure20091110211022
- NallamothuBKHaywardRABatesERBeyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapiesCirculation20081181294130318794402